Based in Switzerland, a well-known country for it healthcare sector, Mediliant was created in 2014 with the acquisition of an entity of Zimmer Biomet by managers and the current CEO, Denis Leissing.

Mediliant has quickly grown in the orthopedic sector as a contract manufacturer with a differentiated offer, and a full-service business model. The company is fully integrated to produce implants from raw material supply to sterile packed products with the highest quality standards for customers.

The company focusses on the traumatology, rachis and extremities implant markets. Mediliant has experienced a constant growth to reach revenues of approx. $20 million in 2018.

The common strategy of Mediliant is to become a leader growing organically and by acquisitions to serve customer globally in Europe, in the US and later in Asia